Omaha, NE – On Monday, May 21, 2012, the United States Supreme Court denied Minneapolis-based
Research and Diagnostic Systems’ (R&D) Petition for Writ of Certiorari in its pending case with Streck,
Inc. The U.S. District Court – Nebraska and the U.S. Court of Appeals for the Federal Circuit both ruled
previously in favor of Streck. The Supreme Court’s decision not to review the case now brings this matter
to a close with Streck prevailing and R&D continuing to be enjoined from making or selling its infringing
products in the United States.

The Court’s decision
confirms the validity of Streck’s patents and that Streck is the first inventor of integrated reticulocyte
controls. Streck is now the only U.S. manufacturer of integrated hematology reticulocyte controls, which
contain a white blood cell five-part differential and a reticulocyte component in one vial. Today’s decision
also confirms the permanent injunction forbidding R&D from manufacturing or selling its integrated
hematology reticulocyte controls called CBC-XE, CBC-4K Plus Retics and CBC-5D Plus Retics.

“We are very pleased with this decision,” said Connie Ryan, President, Streck, Inc. “Our company has a
history of innovation and continues to invest significantly in research and development. Our commitment
to this suit demonstrates our resolve to protect our valuable intellectual property, and the court’s decision
today supports our stance.”

About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The company’s pursuit of innovative solutions has produced an extensive list of patented products. Streck’s core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit

What we offer

Upcoming Events >